Şule Ketenci Ertaş

Şule Ketenci Ertaş

Auto-generated profile, based on publicly available information

Şule Ketenci Ertaş

Department of Internal Medicine Division of Rheumatology Kayseri Acıbadem Hospital Kayseri Turkey

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2019 in Allergy
Verified
Journal Article
Open access
PDF file
RERagıp Ertaş
Ragıp Ertaş
THTomasz Hawro
Tomasz Hawro
SASabine Altrichter
Sabine Altrichter
KÖKemal Özyurt
Kemal Özyurt
KEKemal Erol
Kemal Erol
MMMarcus Maurer
Marcus Maurer
Click on the article title to read more.

2 May 2025 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
NLNihal Lermi
Nihal Lermi
AEALİ EKİN
ALİ EKİN
BYBurcu Yagiz
Burcu Yagiz
FYFatih Yıldırım
Fatih Yıldırım
FAFatih Albayrak
Fatih Albayrak
EDEdiz Dalkılıç
Ediz Dalkılıç

23 July 2025 in Clinical and Translational Allergy
Verified
Journal Article
Open access
RERagıp Ertaş
Ragıp Ertaş
MYMuhammed Burak Yücel
Muhammed Burak Yücel
MTMurat Türk
Murat Türk
ŞEŞule Ketenci Ertaş
Şule Ketenci Ertaş
EKEmek Kocatürk
Emek Kocatürk
MRMelba Munoz Roldan
Melba Munoz Roldan
Background: Short‐term exercise may reduce disease activity in symptomatic dermographism (SD), but its prevalence and short‐ and long‐term effects remain unclear and understudied. This study aims to assess the impact of both short‐term and regular long‐term exercise programs on disease activity in patients with SD.Methods: We performed a short‐term exercise test to assess the disease activity and the critical friction threshold (CFT) using the FricTest before (SDE1) and 10 min after (SDE2) this test on 34 SD patients. Afterward, we asked the patients to carry on a 1‐month regular long‐term exercise program according to the World Health Organization's physical activity recommendations. At the end of this 1‐month period, we performed the short‐term exercise test using the FricTest before (SDE3) and 10 min after (SDE4) the exercise test.Results: Before a 1‐month regular exercise program, 32 of 34 patients (94.1%) showed a reduction in the critical friction threshold after the short‐term exercise test (SDE1; 1.95 ± 0.88 vs. SDE2; 0.81 ± 0.86). After a 1‐month regular exercise program, 29 of 34 patients (85%) showed a reduction in SD symptoms with short‐term exercise test and the FricTest scores were significantly decreased (SDE3; 1.57 ± 0.80 vs. SDE4; 1.01 ± 0.83). After the 1‐month regular exercise program, a statistically significant increase was seen in the patients’ UCT scores and quality of life.Conclusions: Our findings show that short‐term exercise improves SD symptoms, while long‐term regular exercise programs reduce disease symptoms and improve UCT scores and quality of life.

12 March 2024 in Rheumatology Quarterly
Verified
Journal Article
Closed access
SESelime Ermurat
Selime Ermurat
MAMESUDE SEDA AYDOĞDU
MESUDE SEDA AYDOĞDU
MAMehmet Şakir Altuner
Mehmet Şakir Altuner
SZSezgin Zontul
Sezgin Zontul
OCOsman Cure
Osman Cure
SKSüleyman Serdar KOCA
Süleyman Serdar KOCA
Objectives:Idiopathic granulomatous mastitis (IGM) is a rare, benign, chronic inflammatory breast disease of unknown etiology. There is no standardized treatment because its etiology is still unclear. In this multicenter study, we presented the demographic, treatment, and follow-up characteristics of IGM cases monitored by rheumatology clinics. Material and Methods:This retrospective study was conducted in 13 different rheumatology centers. A total of 108 patients with IGM were included in the study. Demographic and clinical data were retrospectively obtained from patient files. Results:The most commonly administered drugs were, in order of frequency, corticosteroid (CS) (91.7%), methotrexate (MTX) (74.1%), antibiotics (63%), non-steroidal anti-inflammatory drugs (41.7%), azathioprine (AZA) (13.9%), colchicine (5.6%), and tumor necrosis factor (TNF) inhibitors (0.9%). The most commonly used form of immunosuppressive (IS) treatment was the MTX and CS combination 78 (72.2%). The ratio of patients receiving CS alone was 19 (17.6%). The ratio of patients who were operated on only and did not use IS drugs was 6.5%. The ratio of patients who received no treatment was 2.8%. Among the drugs used, MTX and CS alone use were independent risk factors for relapse; (p=0.027, p=0.011, respectively). The relapse rate was higher in patients receiving CS alone. Conclusion:IS drugs including CS, MTX, AZA, and TNF inhibitors seem to be efficient for treating IGM. CS alone use is associated with relapse, and the use of other IS drugs such as MTX is particularly effective in reducing relapse in IGM.

1 January 2026 in Dermatologic Therapy
Verified
Journal Article
Open access
MYMuhammed Burak Yücel
Muhammed Burak Yücel
EÜEsranur Ünal
Esranur Ünal
MYMeryem Yiğit
Meryem Yiğit
ŞEŞule Ketenci Ertaş
Şule Ketenci Ertaş
RERagıp Ertaş
Ragıp Ertaş
Background: Dietary strategies in chronic spontaneous urticaria (CSU) have primarily focused on restriction‐based interventions. The potential role of fluid‐restricted intermittent fasting (IF), which may exert immunomodulatory effects, remains underexplored in CSU. This study investigates the efficacy of IF as an adjunctive approach in patients with CSU. Methods: In this prospective observational study, 100 patients with CSU on stable guideline‐directed treatment were allocated based on patient preference to a fasting group ( n = 50, following daily fluid‐restricted IF, median 15.5 h) or a nonfasting control group ( n = 50) for one month. Disease control and activity were assessed using the urticaria control test (UCT) and urticaria activity score (UAS). Results: The fasting group achieved significantly higher UCT scores at one month compared to controls (13 vs. 12, p = 0.001). The change in UCT (ΔUCT) was significantly greater in the fasting group ( p < 0.001). While UAS decreased within the fasting group ( p < 0.001), the between‐group difference in ΔUAS was not significant. Multivariable regression confirmed fasting status as an independent predictor of improved control. Notably, significant improvements were observed even in patients with features of refractory disease, such as elevated CRP and eosinopenia. ROC analysis identified a 16‐h daily fasting threshold for optimal clinical improvement. Conclusions: A structured, prolonged daily fasting regimen is associated with significant improvements in CSU disease control, including in patients with refractory profiles. IF may serve as a practical adjunct to standard therapies.

27 January 2022
Verified
Book
Open access
PDF file
EEEsra Kayacan Erdoğan
Esra Kayacan Erdoğan
SESelime Ermurat
Selime Ermurat
DTDilek Tezcan
Dilek Tezcan
MLMuhammet Li̇mon
Muhammet Li̇mon
ITİpEk Türk
İpEk Türk
FTFatma Tuncer
Fatma Tuncer